Published in Hepatitis Weekly, October 2nd, 2006
"Incomplete virological response to adefovir dipivoxil (ADV) has been observed in patients with lamivudine-resistant HBV infection and may be associated with developing resistance and disease progression. We therefore investigated whether the efficacy of viral suppression could be improved by replacing ADV with tenofovir disoproxit fumarate (TDF)," wrote F. Vanbommel and colleagues, Charite-Universitatsmedizin Berlin.
"Twenty patients with chronic HBV infection (18 HBeAg+),...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly